James Mulay, serving on the board of CG Oncology, Inc. (NASDAQ:CGON), sold 15,600 shares of the company’s common stock on April 17, 2026, according to the transaction disclosure. The shares changed hands at prices between $72.99 and $73.04, producing a weighted average sale price of $73.01 per share and total gross proceeds of $1,138,956.
The disposition was carried out pursuant to a Rule 10b5-1 trading plan Mr. Mulay established on June 6, 2025. That pre-arranged plan governed the timing and execution of the sales reported on April 17.
Prior to selling the shares, Mr. Mulay had obtained the identical block of 15,600 common shares by exercising director stock options. The exercise price for those options was $36.63 per share, which equated to a total exercised amount of $571,428. The disclosure states the director options were fully vested at the time of exercise.
Following the sequence of exercising options and the subsequent sale under the 10b5-1 plan, Mr. Mulay directly holds no common stock in CG Oncology.
The timing of the transaction coincided with CG Oncology's stock trading close to its 52-week high of $73.56. Over the trailing 12-month period the share price has recorded a gain of 256%.
Market valuation commentary included in the reporting notes that InvestingPro analysis considers the stock currently overvalued relative to its Fair Value.
In parallel with the insider activity, CG Oncology disclosed an executive appointment and attracted renewed analyst attention. The company named Jim DeTore as its chief financial officer. DeTore had been serving as the interim principal financial and accounting officer since November 2025 and brings experience from prior roles at Neurogastrx, Proteostasis Therapeutics, and Bluebird Bio.
Several broker-dealers revised their price targets for CG Oncology around the same period. H.C. Wainwright raised its target to $100, noting the importance of the PIVOT-006 trial in intermediate-risk non-muscle invasive bladder cancer. UBS lifted its target to $90 and cited anticipated pivotal trial data expected in the first half of 2026. BofA Securities increased its target to $72, pointing to an improved market share outlook in the bladder cancer adjuvant setting. Truist Securities maintained a Buy rating and a $75 price target while highlighting the sizable commercial opportunity in the disease area.
These company-level changes - the insider sale following an option exercise, the CFO appointment, and the cluster of analyst updates - were disclosed alongside the share-price context and the InvestingPro valuation assessment. The filings indicate Mr. Mulay completed a full exit of his direct common-stock position after exercising vested options and selling the acquired shares under the established trading plan.